The death of a 21-year-old Westport woman in 2018 is at the center of a complaint removed to federal court in Connecticut this week involving GlaxoSmithKline’s mood-stabilizing drug lamotrigine, the generic version of Lamictal.

Attorneys at O’Sullivan McCormack Jensen & Bliss on Wednesday removed the product liability suit against the British pharmaceutical giant to Connecticut District Court. The suit was filed by Koskoff, Koskoff & Bieder on behalf of Alan Doran, administrator for the estate of Rachel Hope Doran.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]